AMPHAmphastar Pharmaceuticals demonstrates strong fundamental performance, particularly in profitability and revenue growth. While its valuation is reasonable, technical indicators suggest a neutral to slightly cautious short-term outlook. The company operates in a resilient sector with ongoing demand for its products.
The pharmaceutical and biotechnology sector is generally stable, with consistent demand for essential medicines. Amphastar's focus on generics and specialized injectables positions it well within this stable landscape, though it may not be at the forefront of highly disruptive thematic trends like AI in drug discovery.
Amphastar Pharmaceuticals exhibits robust financial health with strong profitability, consistent revenue growth, and a manageable debt level. Its solid balance sheet and positive free cash flow generation are key strengths.
Amphastar's technicals show mixed signals. While it's trading above key moving averages, suggesting some upward momentum, several indicators are neutral or lean towards sell, hinting at potential short-term choppiness or consolidation.
| Factor | Score |
|---|---|
| Healthcare Demand | 75 |
| Biotechnology Innovation | 50 |
| Generic Drug Market | 70 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 90 |
| Profitability | 95 |
| Growth | 80 |
| Balance Sheet Health | 75 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 40 |
Positive Earnings Surprises
The company has exceeded earnings per share (EPS) estimates in 7 out of the last 12 reported quarters, with a notable surprise of 21.55% in Q3 2024.
Strong Free Cash Flow Generation
Free cash flow has consistently been positive, reaching $172.345 million in 2024, indicating efficient operations and strong cash generation capabilities.
Significant Short-Term Underperformance
The stock has experienced substantial declines over the past 1M (-11.58%) and 6M (-39.73%) periods, indicating recent negative investor sentiment.
High Price-to-Sales Ratio
The TTM Price-to-Sales (PS) ratio is 1.9, which, while not extremely high in all industries, could be a concern if revenue growth is not robust.
August 2025
7
Next Earnings Date
H: $0.82
A: $0.74
L: $0.60
H: 182.00M
A: 173.41M
L: 161.00M
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
32.40 USD
The 39 analysts offering 1 year price forecasts for AMPH have a max estimate of 38.00 and a min estimate of 29.00.